Nitin Ohri1, Wolfgang A Tomé2, Alejandra Méndez Romero3, Moyed Miften4, Randall K Ten Haken5, Laura A Dawson6, Jimm Grimm7, Ellen Yorke8, Andrew Jackson8. 1. Department of Radiation Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York. 2. Department of Radiation Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York. Electronic address: wtome@montefiore.org. 3. Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. 4. Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado. 5. Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. 6. Radiation Medicine Program, Princess Margaret Cancer Centre and Department of Radiation Oncology, University of Toronto, Ontario, Canada. 7. Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland. 8. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York.
Abstract
PURPOSE: To quantitatively evaluate published experiences with hepatic stereotactic body radiation therapy (SBRT), to determine local control rates after treatment of primary and metastatic liver tumors and to examine whether outcomes are affected by SBRT dosing regimen. METHODS AND MATERIALS: We identified published articles that reported local control rates after SBRT for primary or metastatic liver tumors. Biologically effective doses (BEDs) were calculated for each dosing regimen using the linear-quadratic equation. We excluded series in which a wide range of BEDs was used. Individual lesion data for local control were extracted from actuarial survival curves, and data were aggregated to form a single dataset. Actuarial local control curves were generated using the Kaplan-Meier method after grouping lesions by disease type and BED (<100 Gy10 vs >100 Gy10). Comparisons were made using log-rank testing. RESULTS: Thirteen articles met all inclusion criteria and formed the dataset for this analysis. The 1-, 2-, and 3-year actuarial local control rates after SBRT for primary liver tumors (n = 431) were 93%, 89%, and 86%, respectively. Lower 1- (90%), 2- (79%), and 3-year (76%) actuarial local control rates were observed for liver metastases (n = 290, log-rank P = .011). Among patients treated with SBRT for primary liver tumors, there was no evidence that local control is influenced by BED within the range of schedules used. For liver metastases, on the other hand, outcomes were significantly better for lesions treated with BEDs exceeding 100 Gy10 (3-year local control 93%) than for those treated with BEDs of ≤100 Gy10 (3-year local control 65%, P < .001). CONCLUSIONS: Stereotactic body radiation therapy for primary liver tumors provides high rates of durable local control, with no clear evidence for a dose-response relationship among commonly utilized schedules. Excellent local control rates are also seen after SBRT for liver metastases when BEDs of >100 Gy10 are utilized.
PURPOSE: To quantitatively evaluate published experiences with hepatic stereotactic body radiation therapy (SBRT), to determine local control rates after treatment of primary and metastatic liver tumors and to examine whether outcomes are affected by SBRT dosing regimen. METHODS AND MATERIALS: We identified published articles that reported local control rates after SBRT for primary or metastatic liver tumors. Biologically effective doses (BEDs) were calculated for each dosing regimen using the linear-quadratic equation. We excluded series in which a wide range of BEDs was used. Individual lesion data for local control were extracted from actuarial survival curves, and data were aggregated to form a single dataset. Actuarial local control curves were generated using the Kaplan-Meier method after grouping lesions by disease type and BED (<100 Gy10 vs >100 Gy10). Comparisons were made using log-rank testing. RESULTS: Thirteen articles met all inclusion criteria and formed the dataset for this analysis. The 1-, 2-, and 3-year actuarial local control rates after SBRT for primary liver tumors (n = 431) were 93%, 89%, and 86%, respectively. Lower 1- (90%), 2- (79%), and 3-year (76%) actuarial local control rates were observed for liver metastases (n = 290, log-rank P = .011). Among patients treated with SBRT for primary liver tumors, there was no evidence that local control is influenced by BED within the range of schedules used. For liver metastases, on the other hand, outcomes were significantly better for lesions treated with BEDs exceeding 100 Gy10 (3-year local control 93%) than for those treated with BEDs of ≤100 Gy10 (3-year local control 65%, P < .001). CONCLUSIONS: Stereotactic body radiation therapy for primary liver tumors provides high rates of durable local control, with no clear evidence for a dose-response relationship among commonly utilized schedules. Excellent local control rates are also seen after SBRT for liver metastases when BEDs of >100 Gy10 are utilized.
Authors: Yijun Ding; Harrison H Barrett; Matthew A Kupinski; Yevgeniy Vinogradskiy; Moyed Miften; Bernard L Jones Journal: Med Phys Date: 2019-06-07 Impact factor: 4.071
Authors: Alex R Coffman; Daniel C Sufficool; Joseph I Kang; Chung-Tsen Hsueh; Sasha Swenson; Patrick Q McGee; Gayathri Nagaraj; Baldev Patyal; Mark E Reeves; Jerry D Slater; Gary Y Yang Journal: J Gastrointest Oncol Date: 2021-08
Authors: Joseph I Kang; Daniel C Sufficool; Chung-Tsen Hsueh; Andrew J Wroe; Baldev Patyal; Mark E Reeves; Jerry D Slater; Gary Y Yang Journal: J Gastrointest Oncol Date: 2019-02
Authors: William C Jackson; Holly E Hartman; Laila A Gharzai; Christopher Maurino; David M Karnak; Mishal Mendiratta-Lala; Neehar D Parikh; Charles S Mayo; Randall K Ten Haken; Matthew J Schipper; Kyle C Cuneo; Theodore S Lawrence Journal: Int J Radiat Oncol Biol Phys Date: 2021-04-18 Impact factor: 8.013
Authors: Jimm Grimm; Lawrence B Marks; Andrew Jackson; Brian D Kavanagh; Jinyu Xue; Ellen Yorke Journal: Int J Radiat Oncol Biol Phys Date: 2021-05-01 Impact factor: 8.013
Authors: Jason J Luke; Benjamin E Onderdonk; Sean P Pitroda; Steven J Chmura; Sandeep R Bhave; Theodore Karrison; Jeffrey M Lemons; Paul Chang; Yuanyuan Zha; Tim Carll; Thomas Krausz; Lei Huang; Carlos Martinez; Linda A Janisch; Robyn D Hseu; John W Moroney; Jyoti D Patel; Nikolai N Khodarev; Joseph K Salama; Patrick A Ott; Gini F Fleming; Thomas F Gajewski; Ralph R Weichselbaum Journal: Clin Cancer Res Date: 2020-10-07 Impact factor: 12.531